Imprivata Named Best in KLAS for Identity and Access Management
Healthcare providers rate Imprivata #1 for its identity and access management platform; cite performance, ROI, value, and support for integration...
Patient Care
Palisade Bio Promotes Robert McRae to Chief Operating Officer
Mr. McRae is an industry veteran with a proven track record of operational, clinical, and strategic business development execution Carlsbad, CA,...
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused...
NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
NAARDEN, The Netherlands and MIAMI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma”...
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs Lugano, Switzerland, February 3, 2023 -...
scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
BURLINGTON, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing...
Updated SCAI Guidance Includes Coronary IVL as a Treatment Option in All U.S. Catheterization Labs Regardless of Surgical Backup Status
Guidance Expands Number of Hospitals that Can Access IVL to Include Sites Where Calcium Modification Tools Were Previously Not RecommendedSANTA...
scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update
Commercial launch planned for February 20, 2023BURLINGTON, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical...
AmMax Bio Announces First Patients Dosed in Phase 2b Study of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Study designed to optimize treatment regimen and evaluate efficacy over six-month dosing period Initial results expected in second half of...
MIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Director
Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead MIMEDX MARIETTA,...
Sight Sciences Announces 1,000th TearCare® Customer Installation
Over 1,000 Professional Eye Care Practices Have integrated the TearCare® System to Treat Root Cause of Dry Eye Disease due to...
OpGen subsidiary Ares Genetics announces granting of key patent in China
Patent covers the identification and diagnostic use of genomic variants for the diagnosis of antibiotic resistant bacteriaThe China National Intellectual...
STERIS to Host a Conference Call for Fiscal 2023 Third Quarter Financial Results on February 9, 2023
DUBLIN, IRELAND, Jan. 25, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it...
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
Study demonstrates targeted delivery devices functioned as designed when administered with food, potentially enabling non-fasted administrationSAN DIEGO, Jan. 19, 2023...
AmMax Bio’s AMB-05X Receives EMA PRIME Designation for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
AMB-05X is the First and Only Investigational Drug Candidate to Receive PRIME Designation for the Treatment of TGCT PRIME Designation...
BioSig Issues Shareholder Update to Highlight Recent Achievements and Ongoing Developments
Westport, CT, Jan. 19, 2023 (GLOBE NEWSWIRE) -- To date, the Company's FDA 510(k)-cleared PURE EP™ System has been used...
Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)
Collaboration enables TGen to gain access to data generated on prototype versions of Nautilus’ next-generation proteome analysis platform to advance...
The MUHC Foundation welcomes new board members
Eight distinguished business and community leaders joined the MUHC Foundation’s Board of Directors in 2022. The MUHC Foundation welcomes new...
NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
-- Achieved primary endpoint with statistically significant reduction in LDL-C (p < 0.0001) ---- Median percent change in LDL-C of...
VitalHub Announces Licensing Agreement With East Sussex Healthcare NHS Trust
TORONTO, Jan. 16, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the "Company" or "VitalHub") is pleased to announce a licensing agreement...